MariTide is a monthly injection that investors hope could compete against existing weight loss drugs from Novo Nordisk and ...
Amgen’s most advanced obesity asset MariTide is entering Maritime—that is, a phase 3 program that includes two freshly ...
Elsewhere in the obesity space — Amgen has initiated Phase 3 trials of its obesity drug MariTide, one in overweight and obese ...
Phase 3 studies for Amgen’s closely watched obesity drug were posted on a federal database. Elsewhere, the FDA cleared for ...
Amgen (NASDAQ:AMGN) stock in focus as company starts Phase 3 trials for obesity drug MariTide, aiming to challenge Eli Lilly ...
Dividend investors don't buy shares of companies hoping they will suspend their payouts soon. The longer a corporation ...
Amgen said it has started two critical late-stage trials for its experimental weight loss injection, MariTide, another step in its bid to enter the booming obesity drug market. MariTide is a ...
What's considered excellent revenue growth depends on the industry. With that context in mind, consider that Eli Lilly's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results